Neurocrine Biosciences News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

14.12.24	Neurocrine's CRENESSITY Gains FDA Approval For Treating Congenital Adrenal Hyperplasia (RTTNews)
02.12.24	Biotech Stocks Facing FDA Decision In December 2024 (RTTNews)
07.11.24	Neurocrine's Ingrezza Shows Positive Data For Reduction Of Huntington's Disease Chorea (RTTNews)
04.11.24	Neurocrine Says Tardive Dyskinesia Patients Saw Holistic Improvements After Ingrezza Treatment (RTTNews)
30.10.24	Neurocrine Biosciences Lifts FY24 INGREZZA Sales View, Plans $300 Mln Buyback; Stock Up - Update (RTTNews)
30.10.24	Neurocrine Biosciences Inc Q3 Profit Increases, Beats Estimates (RTTNews)
30.09.24	Neurocrine Biosciences Announces Interim Data Of KINECT-HD2 Study Of Ingrezza Capsules (RTTNews)
28.08.24	Neurocrine Reports Positive Phase 2 Data For NBI-1117568 In Adults With Schizophrenia; Stock Down (RTTNews)
01.08.24	Neurocrine Biosciences Raises 2024 INGREZZA Net Product Sales Guidance (RTTNews)
01.08.24	Neurocrine Biosciences Inc Q2 Profit Decreases, But Beats Estimates (RTTNews)
18.07.24	Neurocrine Biosciences Launches INGREZZA SPRINKLE Capsules - Quick Facts (RTTNews)
01.07.24	Neurocrine's NDA For Crinecerfont To Treat Congenital Adrenal Hyperplasia Gets Priority Review (RTTNews)
03.06.24	Neurocrine Biosciences' CAHtalyst Phase 3 Studies Of Crinecerfont Meet Primary Goals (RTTNews)
29.05.24	Neurocrine Biosciences CEO Kevin Gorman To Retire; Appoints Kyle Gano As CEO-elect (RTTNews)
01.05.24	Neurocrine Biosciences Inc Q1 Earnings Summary (RTTNews)
01.05.24	FDA Approves Neurocrine Biosciences' INGREZZA Sprinkle Capsules (RTTNews)
23.04.24	Neurocrine's Phase 2 SAVITRI Study Meets Primary Endpoint For NBI-1065845 In Adults With MDD (RTTNews)
28.03.24	Biotech Stocks Facing FDA Decision In April 2024 (RTTNews)
07.02.24	Neurocrine Biosciences Inc Q4 Profit Rises, Beats estimates (RTTNews)
02.01.24	Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
05.12.23	Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia (PR Newswire)
01.12.23	Neurocrine Biosciences to Host Analyst Day on December 5, 2023 (PR Newswire)
13.11.23	Neurocrine Biosciences Reaches Settlement On INGREZZA ANDA Litigation (RTTNews)
13.11.23	Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation (PR Newswire)
09.11.23	Neurocrine Biosciences Provides Development Pipeline Update (PR Newswire)
08.11.23	Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia (PR Newswire)
08.11.23	Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference (PR Newswire)
02.11.23	Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Stu... (PR Newswire)
31.10.23	Neurocrine Biosciences Inc Q3 Profit Increases, beats estimates (RTTNews)
31.10.23	Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance (PR Newswire)
10.10.23	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results (PR Newswire)
05.10.23	Neurocrine Biosciences: CAHtalyst Pediatric Study Meets Primary Endpoint - Quick Facts (RTTNews)
05.10.23	Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints (PR Newswire)
21.09.23	Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023 (PR Newswire)
14.09.23	Neurocrine : FDA Accepts NDA For Ingrezza Oral Granules Sprinkle Formulation (RTTNews)
14.09.23	Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation (PR Newswire)
12.09.23	Neurocrine Biosciences Reports Positive Top-line Data From Phase 3 Study Of Crinecerfont (RTTNews)
12.09.23	Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) (PR Newswire)
11.09.23	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults (PR Newswire)
31.08.23	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
29.08.23	Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and ... (PR Newswire)
28.08.23	Neurocrine Reveals New Data On Ingrezza With Improvements In HD Chorea In Huntington's Disease (RTTNews)
28.08.23	Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease (PR Newswire)
18.08.23	Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease (PR Newswire)
01.08.23	Neurocrine Biosciences Inc Q2 Earnings Summary (RTTNews)
01.08.23	Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance (PR Newswire)
11.07.23	Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors (PR Newswire)
11.07.23	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results (PR Newswire)
15.06.23	Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023 (PR Newswire)
08.06.23	Neurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.11.24		Anleger in New York halten sich zurück: NASDAQ Composite in der Verlustzone
30.10.24		Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach
30.10.24		Handel in New York: NASDAQ Composite verbucht Verluste
30.10.24		Gute Stimmung in New York: NASDAQ Composite mittags fester
30.10.24		Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone
28.08.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite präsentiert sich zum Handelsende leichter
28.08.24		Handel in New York: So performt der NASDAQ Composite am Mittwochnachmittag
28.08.24		Schwache Performance in New York: So steht der NASDAQ Composite aktuell